Newbridge Financial Services Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-12
Closed -$5 1252
2024
Q1
$5 Hold
12
﹤0.01% 1175
2023
Q4
$9 Hold
12
﹤0.01% 1113
2023
Q3
$10 Hold
12
﹤0.01% 1277
2023
Q2
$22 Sell
12
-1
-8% -$3 ﹤0.01% 1337
2023
Q1
$46 Hold
13
﹤0.01% 1380
2022
Q4
$48 Hold
13
﹤0.01% 1419
2022
Q3
$0 Hold
13
﹤0.01% 1505
2022
Q2
$0 Hold
13
﹤0.01% 1559
2022
Q1
$0 Hold
13
﹤0.01% 1596
2021
Q4
$1K Hold
13
﹤0.01% 1383
2021
Q3
$1K Hold
13
﹤0.01% 1350
2021
Q2
$1K Hold
13
﹤0.01% 1411
2021
Q1
$2K Hold
13
﹤0.01% 1214
2020
Q4
$2K Hold
13
﹤0.01% 989
2020
Q3
$2K Buy
+13
New +$2.12K ﹤0.01% 941

Other funds holding NBSE

Newbridge Financial Services Group's NBSE Position: Q2 2024 in Review

Newbridge Financial Services Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 12 shares — an estimated $5 sold.

Newbridge Financial Services Group first reported a position in NBSE in Q3 2020 and held it in 15 quarters. The position peaked at $2K in Q1 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

  • Newbridge Financial Services Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 12 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $5.
  • Newbridge Financial Services Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2020 and held it in 15 quarters.
  • Newbridge Financial Services Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $2K in Q1 2021.
  • 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Newbridge Financial Services Group's 13F filing for Q2 2024, filed 11 Sep 2024.